Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies

Opinion
Video

This segment introduces a discussion on the MARIPOSA-2 trial evaluating amivantamab plus chemotherapy or amivantamab, lazertinib and chemotherapy in EGFR-mutant NSCLC after osimertinib progression.

•How frequently does the disease develops resistance to osimertinib in the frontline setting?

•How does amivantamab address the unmet needs of patients who develop resistance to osimertinib?

Recent Videos
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Two experts are featured in this series.
Related Content
The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line non-squamous NSCLC.

Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC

Roman Fabbricatore
November 30th 2025
Article

The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line nonsquamous NSCLC.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Zidesamtinib elicited positive activity in patients with advanced ROS1-positive NSCLC who previously received a ROS1 TKI in the phase 1/2 ARROS-1 trial.

FDA Accepts NDA for Zidesamtinib in Pretreated Advanced ROS1+ NSCLC

Tim Cortese
November 20th 2025
Article

Zidesamtinib elicited positive activity in patients with advanced ROS1-positive NSCLC who previously received a ROS1 TKI in the phase 1/2 ARROS-1 trial.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.

EU Approves Subcutaneous Pembrolizumab in All Approved Indications

Roman Fabbricatore
November 19th 2025
Article

The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.

Duality Biotherapeutics entered an exclusive license agreement with Avenzo Therapeutics in January 2025.

AVZO-1418/DB-1418 Earns FDA Fast Track Designation For EGFR-Mutated NSCLC

Roman Fabbricatore
November 14th 2025
Article

The EGFR/HER3 bispecific ADC is being evaluated in an open-label phase 1/2 study to assess its safety, tolerability, and activity in advanced solid tumors.